Clinical Trials Browser

Terminated × Interventional × Solid Tumors × Clear all

NCT05839600 2026-05-22

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Phase 1 Terminated

10 enrolled 12 charts

Other solid neoplasm

Solid Tumors

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

NCT05976334 2025-10-06

An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

3 enrolled 19 charts

Other solid neoplasm

Solid Tumors

NCT05387265 2025-07-14

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT04613492 2025-06-24

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT04405778 2025-05-29

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT05164666 2025-05-29

A Study of TAK-103 in Adult With Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT04642365 2025-05-21

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

Phase 1 Terminated

49 enrolled 31 charts

Other solid neoplasm

Solid Tumors

NCT04237649 2025-05-18

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Phase EARLY_PHASE1 Terminated

Other solid neoplasm

Solid Tumors

NCT01127178 2024-10-10

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Phase 1 Terminated

12 enrolled 13 charts

Other solid neoplasm

Solid Tumors

NCT05996445 2024-08-23

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT04158583 2024-03-04

A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors

Phase 1 Terminated

76 enrolled 30 charts

Other solid neoplasm

Solid Tumors

NCT01190644 2023-11-29

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

Phase 2 Terminated

5 enrolled 11 charts

Other solid neoplasm

Solid Tumors

NCT03225105 2023-11-22

M3541 in Combination With Radiotherapy in Solid Tumors

Phase 1 Terminated

15 enrolled 18 charts

Other solid neoplasm

Solid Tumors

NCT05129280 2023-08-04

A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT02700308 2022-07-28

KYPHO-01

Phase 2 Terminated

Other solid neoplasm

Solid Tumors

NCT00560716 2021-12-22

A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Phase 1/2 Terminated

34 enrolled 27 charts

Other solid neoplasm

Solid Tumors

NCT03539484 2020-09-03

A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors

Phase 1 Terminated

26 enrolled 30 charts

Other solid neoplasm

Solid Tumors

NCT01369433 2020-09-01

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

Phase NA Terminated

225 enrolled 7 charts

Other solid neoplasm

Solid Tumors

NCT02648711 2020-05-28

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT01548924 2020-04-17

Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT02559492 2019-09-25

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT01431534 2019-03-01

MK-8669-056

Phase 1 Terminated

20 enrolled 10 charts

Other solid neoplasm

Solid Tumors

NCT01463696 2018-08-27

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Phase 1 Terminated

48 enrolled 17 charts

Other solid neoplasm

Solid Tumors

NCT01930292 2016-03-24

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT01809912 2015-11-26

Safety Study of MG1102 in Patients With Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT00360867 2015-10-15

An Open Label Treatment Extension Study of AMG 706

Phase 2 Terminated

Other solid neoplasm

Solid Tumors

NCT01110083 2013-10-22

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT00550199 2013-08-19

LBH589 and Gemcitabine in the Treatment of Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT00497731 2009-06-22

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Phase 1 Terminated

Other solid neoplasm

Solid Tumors

NCT00165373 2007-12-28

rhEndostatin Protein Involving Pediatric Patients With Cancer

Phase 1 Terminated

Other solid neoplasm

Solid Tumors